A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)
A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993) is a PHASE2 clinical asset sponsored by National Cancer Institute (NCI) in Colorectal Cancer. SEO and diligence focus: becatecarin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Colorectal Cancer
Modality: small molecule
Target: becatecarin
Sponsor: National Cancer Institute (NCI)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: becatecarin
View original source fields
Condition raw: Colorectal Cancer
Condition normalized: Colorectal Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: becatecarin
Target normalized: becatecarin